Sirona Biochem Corp. Share Price

Equities

SBM

CA82967M1005

Biotechnology & Medical Research

Market Closed - Toronto S.E. 10:39:13 26/04/2024 pm IST 5-day change 1st Jan Change
0.065 CAD -7.14% Intraday chart for Sirona Biochem Corp. +8.33% -45.83%

Financials

Sales 2022 672K 491K 40.98M Sales 2023 34.78K 25.42K 2.12M Capitalization 21.44M 15.67M 1.31B
Net income 2022 -3M -2.19M -183M Net income 2023 -2M -1.46M -122M EV / Sales 2022 48.8 x
Net Debt 2022 48.04K 35.12K 2.93M Net Debt 2023 1.61M 1.18M 98.23M EV / Sales 2023 663 x
P/E ratio 2022
-8.81 x
P/E ratio 2023
-8.43 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-7.14%
1 week+8.33%
3 months-35.00%
6 months-23.53%
Current year-45.83%
More quotes
1 week
0.06
Extreme 0.06
0.07
1 month
0.06
Extreme 0.055
0.07
Current year
0.06
Extreme 0.055
0.12
1 year
0.06
Extreme 0.055
0.18
3 years
0.06
Extreme 0.055
0.38
5 years
0.06
Extreme 0.055
0.69
10 years
0.06
Extreme 0.055
0.69
More quotes
Managers TitleAgeSince
Chief Executive Officer - 19/06/19
Director of Finance/CFO - 29/09/29
Chief Tech/Sci/R&D Officer - 31/11/31
Members of the board TitleAgeSince
Chief Executive Officer - 19/06/19
Director/Board Member - 19/06/19
Director of Finance/CFO - 29/09/29
More insiders
Date Price Change Volume
26/24/26 0.065 -7.14% 56,001
25/24/25 0.07 +16.67% 25,009
24/24/24 0.06 -7.69% 10,000
22/24/22 0.065 +8.33% 57,416

Delayed Quote Toronto S.E., April 26, 2024 at 10:39 pm IST

More quotes
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).
More about the company